Should You Investigate Dekel Agri-Vision plc (LON:DKL) At UK£0.031?

Published
June 25, 2022
AIM:DKL
Source: Shutterstock

Dekel Agri-Vision plc (LON:DKL), is not the largest company out there, but it saw significant share price movement during recent months on the AIM, rising to highs of UK£0.057 and falling to the lows of UK£0.031. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Dekel Agri-Vision's current trading price of UK£0.031 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Dekel Agri-Vision’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Dekel Agri-Vision

What is Dekel Agri-Vision worth?

Dekel Agri-Vision is currently expensive based on my price multiple model, where I look at the company's price-to-earnings ratio in comparison to the industry average. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 25.8x is currently well-above the industry average of 15.91x, meaning that it is trading at a more expensive price relative to its peers. But, is there another opportunity to buy low in the future? Since Dekel Agri-Vision’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from Dekel Agri-Vision?

earnings-and-revenue-growth
AIM:DKL Earnings and Revenue Growth June 25th 2022

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for Dekel Agri-Vision. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? DKL’s optimistic future growth appears to have been factored into the current share price, with shares trading above industry price multiples. However, this brings up another question – is now the right time to sell? If you believe DKL should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on DKL for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the positive outlook is encouraging for DKL, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

If you want to dive deeper into Dekel Agri-Vision, you'd also look into what risks it is currently facing. For example, Dekel Agri-Vision has 3 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

If you are no longer interested in Dekel Agri-Vision, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.